Management of Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction

Manreet Kanwar, Ryan J. Tedford, Richa Agarwal, Megan M. Clarke, Claire Walter, George Sokos, Srinivas Murali, Raymond L. Benza

Research output: Contribution to journalReview article

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.

Original languageEnglish (US)
Article number501
Pages (from-to)1-9
Number of pages9
JournalCurrent hypertension reports
Volume16
Issue number12
DOIs
StatePublished - Oct 11 2014

    Fingerprint

Keywords

  • Diastolic dysfunction
  • HFpEF-PH
  • Heart failure
  • Pharmacology
  • Preserved ejection fraction
  • Pulmonary artery remodeling
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Kanwar, M., Tedford, R. J., Agarwal, R., Clarke, M. M., Walter, C., Sokos, G., Murali, S., & Benza, R. L. (2014). Management of Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction. Current hypertension reports, 16(12), 1-9. [501]. https://doi.org/10.1007/s11906-014-0501-5